A research team from the Germans Trias i Pujol Research Institute (IGTP) has developed a new experimental model based on induced pluripotent stem cells (iPSCs) that makes it possible to reproduce in the laboratory the progression of tumors associated with neurofibromatosis type 1 (NF1), from benign forms to aggressive malignant tumors. The study, published in Nature Communications, also identifies a potential therapeutic strategy based on the combination of the drugs olaparib and selumetinib.
This article was originally published by MedicalXpress. For more details, images, and references:
Read Full Original Article ↗